Medical Grade Footwear Market

The International Diabetes Federation (IDF) counts 589 million adults with diabetes, while a Medicare beneficiary at risk of a foot ulcer may claim just one pair of extra-depth shoes a year: between those two numbers sits the medical grade footwear trade. Medical grade footwear covers extra-depth therapeutic shoes, multi-density inserts, custom-moulded orthopaedic shoes, post-operative and offloading shoes, and medical-grade sandals and slippers that are prescribed or fitted to protect a neuropathic, deformed or healing foot. Douglas Insights counts 63.84 million dispensed pairs in 2025 at an average manufacturer price of USD 68.37, which multiplies to USD 4.36 billion. Our model reaches USD 7.79 billion by 2035, a revenue compound annual growth rate (CAGR) of 5.97%, from 4.3% volume growth and 1.6% price growth. Ownership of the best-known brand changed on 8 October 2025, when Enovis completed the sale of its Dr. Comfort footcare business to Promus Equity Partners for up to USD 60 million. The analysis belongs to our orthopaedic devices coverage and follows the Douglas Insights research methodology.

Which medical grade footwear product earns the most: extra-depth shoes, inserts or custom-moulded pairs?

Extra-depth therapeutic shoes earn the most medical grade footwear revenue, 38.7% of 2025 value or USD 1.69 billion, because they are the default prescription for an at-risk diabetic foot. Multi-density therapeutic inserts are the fastest-growing product at 7.2% a year, reaching USD 1.87 billion by 2035.

Extra-depth therapeutic shoes hold USD 1.69 billion since every Medicare depth-shoe claim starts with a pair of them, and their extra internal volume makes room for an insert; they grow 5.55% a year to USD 2.90 billion. Multi-density therapeutic inserts carry USD 934.0 million, a 21.4% share, because the payer rules allow three insert pairs for every depth-shoe pair, so the insert is the repeat purchase.

Custom-moulded orthopaedic shoes are worth USD 755.1 million, or 17.3%. Each pair is built over a cast or scan of a badly deformed foot, such as a Charcot foot or a partial amputation, which keeps volumes small but prices high; growth is the slowest at 4.6% a year. Post-operative and offloading shoes take USD 606.7 million, a 13.9% share, sold after bunion, hammertoe and forefoot surgery and to patients with an open ulcer.

Medical-grade sandals and slippers are the smallest product at USD 379.7 million, or 8.7%, growing 6.6% a year to USD 719.5 million as warm-climate buyers in Asia Pacific and the Gulf ask for protective open footwear. Inserts lead growth: digital foot scanning and computer-aided design and manufacturing (CAD/CAM) milling cut the cost of a custom insert, so podiatrists prescribe them more often.

Why are neuropathy and foot-ulcer recurrence lifting demand for medical grade footwear?

Dispensed medical grade footwear pairs grow 4.3% a year to 2035 from four forces. Diabetes prevalence adds 1.9 points, ulcer-recurrence prevention 1.1 points, foot surgery and ageing 0.7 points and digital scanning 0.6 points, which together make the whole volume leg.

Diabetes prevalence adds 1.9 points

The patient pool is the first force. The IDF Diabetes Atlas, published on 7 April 2025, puts adults with diabetes at 589 million in 2024 and projects 853 million by 2050, a 1.43% yearly rise; it also finds 252 million adults unaware of their condition. In the United States, the Centers for Disease Control and Prevention (CDC) counts 40.1 million people with diabetes, 12.0% of the population, of whom 11.0 million are undiagnosed. Douglas Insights puts the effect at 1.9 points of yearly medical grade footwear volume, above the raw prevalence rate, because more diagnosis means more foot screening and more prescriptions for therapeutic shoes.

Ulcer-recurrence prevention adds 1.1 points

Recurrence is the second force. Up to 34% of people with type 2 diabetes develop a foot ulcer in their lifetime, and after healing about 40% recur within the first year and 65% within three years, according to a review in Translational Medicine at UniSa. Every healed ulcer becomes a prescription for protective shoes and custom inserts. Douglas Insights models 1.1 points of volume from this cycle, which is why multi-density inserts grow fastest of all medical grade footwear products.

Foot surgery and ageing add 0.7 points, digital scanning 0.6 points

Forefoot surgery in older adults is the third force: each bunion or hammertoe correction needs a post-operative shoe during healing, and older patients with arthritis buy medical-grade sandals and depth shoes without a diabetes diagnosis at all. We place that effect at 0.7 points. Digital fitting is the fourth. Aetrex reports more than 10,000 foot scanners worldwide that have run more than 40 million scans, now above 2.5 million a year, and scan-to-insert workflows shorten a fitting from weeks to days. Douglas Insights credits 0.6 points to scanning and online re-ordering. The four contributions, 1.9, 1.1, 0.7 and 0.6 points, add to the 4.3% volume leg, while the price leg adds 1.6% a year as custom and CAD/CAM inserts take share. The Dr. Comfort sale of 8 October 2025 also matters here: a standalone owner focused on diabetic footwear is more likely to invest in fitting tools than a diversified orthopaedics group.

Which barriers keep prescribed medical grade footwear off at-risk diabetic feet?

Three barriers remove about 1.5 points from medical grade footwear volume growth: paperwork 0.6 points, patient adherence 0.5 points and out-of-pocket cost in poorer markets 0.4 points. Without them, dispensed pairs would grow near 5.8% a year rather than 4.3%.

Paperwork removes 0.6 points. Under the Centers for Medicare and Medicaid Services (CMS) policy article A52501, revised with effect from 5 December 2024, the certifying physician must be an M.D. or D.O., must see the patient for diabetes management within 6 months before delivery and must sign within 3 months; the prescriber must also document an in-person evaluation and a separate fitting at delivery. A missing signature turns the medical grade footwear claim into a denial.

Adherence removes 0.5 points. A shoe that is prescribed but left in the cupboard protects nothing, and people with neuropathy often prefer their old shoes indoors, where many ulcers start.

Cost removes 0.4 points. The IDF finds that 3 in 4 adults with diabetes live in low- and middle-income countries, where depth shoes and inserts are bought out of pocket. A pair is replaced late or not at all, so medical grade footwear volume in those markets trails the patient count by a wide margin.

How much does a depth shoe and insert set cost a payer per pair?

A pair of medical grade footwear earned its maker USD 68.37 on average in 2025, and Douglas Insights expects USD 80.13 by 2035. Payer fee lines frame the bands: Montana Medicaid pays USD 90.63 for a depth shoe and USD 271.80 for a custom-moulded shoe.

The Montana Medicaid podiatry fee schedule, effective 1 January 2026, lists HCPCS (Healthcare Common Procedure Coding System) code A5500 at USD 90.63 per depth shoe, A5501 at USD 271.80 per custom-moulded shoe, A5512 at USD 36.96 per direct-formed multi-density insert and both A5513 and A5514 at USD 55.16 per custom-moulded or CAD/CAM insert. Manufacturer prices sit below these payer fees, since the supplier keeps a fitting margin.

The average climbs 1.6% a year because the mix moves toward CAD/CAM inserts and custom shoes, not because fee lines rise fast. A Medicare year of one depth-shoe pair plus three insert pairs is worth about USD 201.51 at the Montana A5500 and A5512 rates, against USD 382.12 for a custom-moulded pair with two CAD/CAM insert pairs, a gap of 1.9 times.

Which companies supply medical grade footwear after Enovis sold Dr. Comfort?

Douglas Insights estimates a 4.6% share of 2025 medical grade footwear value, or USD 200.8 million, for the leader, Dr. Comfort, ahead of Aetrex and Orthofeet. The top three suppliers hold only about 10.1%, a basis built from product ranges and channel reach, because local orthopaedic shoemakers fill most of the market.

Dr. Comfort, based in Mequon, Wisconsin, built its position on depth shoes and inserts sold through Medicare suppliers, and DJO Global described it as the number one share holder in diabetic footwear when it agreed to buy it for about USD 254.6 million. Enovis completed the sale of the business to Chicago-based Promus Equity Partners on 8 October 2025, for USD 45 million upfront and up to USD 15 million more on milestones, as the Enovis release sets out.

Aetrex, with an estimated 3.1% share or USD 135.3 million, built its place on foot scanning: more than 10,000 scanners and over 40 million scans feed its inserts and footwear. Orthofeet of Northvale, New Jersey, takes about 2.4%, or USD 104.8 million, selling shoes, insoles and socks direct to consumers managing diabetes, arthritis or swelling.

DARCO International of Huntington, West Virginia, founded by podiatrist Dr. H. Darrel Darby, leads in post-operative and wound care shoes, with offices in Germany, the UK and India. Apex Foot Health Industries, the former Aetrex division now owned by Orthotic Holdings Inc of Ronkonkoma, New York, supplies depth shoes and inserts to orthotic labs. Hanger Clinic does not make shoes at scale but runs roughly 800 patient care locations with about 1,500 clinicians who fit custom and extra-depth shoes, a large fitting channel in the US. Readers tracking the consumer side should see our Footwear Market.

Where is medical grade footwear spending growing fastest, from Medicare to Asia Pacific?

North America leads medical grade footwear with USD 1.77 billion in 2025, or 40.6%, because Medicare and private plans pay for depth shoes and inserts. Asia Pacific grows fastest at 8.75% a year, from USD 955.9 million to USD 2.21 billion by 2035, as diagnosis and podiatry spread.

North America reaches USD 2.79 billion by 2035 at 4.65% a year, slowed by the paperwork load described above. Europe holds USD 1.19 billion, a 27.3% share, and grows 4.85% a year to USD 1.91 billion; its strength is a trade of orthopaedic shoemakers who build custom-moulded pairs. Asia Pacific, at 21.9% of 2025 value, carries most of the world’s adults with diabetes yet spends the least per patient, which is exactly why its growth rate is the highest.

Latin America is the wildcard at USD 275.0 million, growing 7.1% a year to USD 546.0 million if public diabetes programmes in Brazil and Mexico add footwear to foot-care protocols. The Middle East and Africa is the smallest region at USD 170.1 million, growing 6.87% a year to USD 330.7 million, led by Gulf states with high diabetes rates and private insurance.

Do DME suppliers, podiatrists or online stores dispense most medical grade footwear?

Douglas Insights finds that durable medical equipment (DME) suppliers and orthotic clinics dispense about 52.4% of 2025 medical grade footwear value, because insured claims need an in-person fitting. Podiatry practices take about 29.3% and Online and retail pharmacy about 18.3%, the fastest-growing channel.

DME suppliers and orthotic clinics lead because the CMS rules require a documented evaluation before the shoe is chosen and a fitting at delivery, steps that a store cannot do. Podiatry practices dispense in the room where the ulcer was treated, which raises adherence. Online and retail pharmacy grows fastest, since patients paying cash re-order the same insert or depth shoe without a visit, and Orthofeet built its brand on that route.

By end user, Diabetic foot patients account for about 71.6% of value, Post-surgical and trauma patients for about 16.9% and Arthritis and deformity patients for about 11.5%. Ulcers that do open fall into our Wound Care Market, and offloading shoes are the link between the two.

Are custom-moulded orthopaedic shoes losing ground to CAD/CAM medical inserts?

Yes, slowly: custom-moulded orthopaedic shoes fall from 17.3% of medical grade footwear value in 2025 to about 15.2% in 2035, while multi-density inserts rise from 21.4% to about 24.1%. A milled insert inside a depth shoe now handles many feet that once needed a custom shoe.

The payer fee gap explains the shift. A custom-moulded shoe at USD 271.80 costs three times a depth shoe at USD 90.63, and an A5514 CAD/CAM insert at USD 55.16 inside the cheaper shoe protects most moderate deformities. Custom-moulded pairs keep their place for Charcot collapse and partial foot amputation, where no standard last fits.

Which rules make a corrective shoe a Class I device and a Medicare benefit?

A corrective shoe is a Class I limb orthosis under US rule 21 CFR 890.3475, exempt from premarket notification. Medicare covers medical grade footwear only for diabetes with a qualifying foot condition, at 1 depth-shoe pair and 3 insert pairs a year.

The Food and Drug Administration (FDA) rule lists a corrective shoe among its examples of a limb orthosis, places it in Class I and exempts it from most good manufacturing practice requirements except records and complaint files. Entry is therefore easy, which keeps many small makers in medical grade footwear and caps pricing power.

Payment rules are stricter than product rules. CMS policy article A52501 allows either one pair of custom-moulded shoes with 2 extra insert pairs, or one pair of depth shoes with 3 insert pairs, per calendar year; anything more is denied. The patient must have diabetes plus one of six conditions: prior partial foot amputation, prior ulcer, pre-ulcerative callus, neuropathy with callus, foot deformity or poor circulation. Douglas Insights treats these quantity limits as the ceiling on US volume per patient.

How far apart do the slower and faster medical grade footwear cases land in 2035?

Medical grade footwear reaches USD 7.79 billion in 2035 in the base case. The slower case lands at USD 6.42 billion, a 3.93% CAGR, and the faster case at USD 9.36 billion, a 7.92% CAGR, so USD 2.94 billion separates the outer cases.

The slower case runs volume at 3.0% and price at 0.9%: CMS documentation stays as tight as policy article A52501 requires today, adherence stays low and Asia Pacific buyers stay with generic soft shoes. The faster case runs volume at 5.6% and price at 2.2%: diagnosis closes part of the 252 million undiagnosed gap counted by the IDF, scan-based inserts become routine, and Promus Equity Partners, the new owner of Dr. Comfort after the Enovis sale, pushes direct and clinic channels harder.

Add one point of yearly pair growth and the 2035 medical grade footwear total gains about USD 780.3 million; take one away and it loses about USD 715.8 million. Outside forecasts we read for diabetic footwear span 6.19% to 7.9% a year, and our 5.97% sits just under that span because we exclude non-prescribed comfort shoes sold as diabetic-friendly.

Douglas Exclusive: the At-Risk Foot Coverage Register

The At-Risk Foot Coverage Register is a Douglas Insights model, not an official register, built from 14 inputs. Those inputs are the IDF counts of 589 million and 853 million adults with diabetes, the CDC count of 40.1 million, our 15.6% at-risk foot ratio, 5 regional diabetes allocations and our 5 regional medical grade footwear values. It counts how much each region spends per at-risk adult.

The finding is a gap of 13.7 times. North America spends USD 224.0 on medical grade footwear per at-risk adult, while Asia Pacific spends USD 16.3, even though Asia Pacific holds 58.81 million of the 91.9 million at-risk adults in our model. Europe sits at USD 115.7, Latin America at USD 45.3 and the Middle East and Africa at USD 19.3.

The register explains our regional growth rates: Asia Pacific, the region with the lowest spend per at-risk foot, grows fastest, because each new diagnosis there turns into a first purchase rather than a replacement.

Methodology: how the model turns 589 million adults with diabetes into dispensed pairs?

Douglas Insights applies a 15.6% at-risk foot ratio to the IDF’s 589 million adults, giving 91.9 million at-risk adults; 31.5% are supplied in a year at 1.62 pairs each, or 46.9 million pairs. Post-surgical, trauma and arthritis buyers add 16.94 million, for 63.84 million medical grade footwear pairs.

Multiplied by USD 68.37, that is USD 4.36 billion. The 2026 value is USD 4.63 billion. Pairs grow 4.3% a year to 97.26 million in 2035 at USD 80.13 each, giving USD 7.79 billion. The model covers 5 regions, 5 product segments, 3 channels and 3 end-user groups, and draws on 13 documents read for this edition.

Regional values sum to the global total within USD 0.1 million in 2025 and 2035; segment values sum exactly in 2025 and within 0.35% in 2035. Three cross-checks were run. The CDC count of 40.1 million is 79.1% of our 50.7 million North American allocation, consistent with Canada and Mexico making up the rest. Our 5.97% CAGR sits 0.22 points under the lowest published rate we read. A depth-shoe Medicare year at USD 201.51 in payer fees is about 2.9 times our USD 68.37 average manufacturer price per pair, consistent with one shoe and three inserts per claim plus a supplier margin. Readers interested in fracture immobilisation can compare our Orthopedic Splints and Casts Market.

Sources

1. International Diabetes Federation IDF Diabetes Atlas 11th edition news release (2025)
2. Centers for Medicare and Medicaid Services Therapeutic Shoes for Persons with Diabetes, Policy Article A52501 (2024)
3. Enovis Enovis completes sale of its Dr. Comfort footcare solutions business (2025)
4. eCFR, US Government 21 CFR 890.3475 Limb orthosis (2026)
5. Montana Department of Public Health and Human Services Podiatry Services Fee Schedule, January 2026 (2026)
6. Centers for Disease Control and Prevention National Diabetes Statistics Report (2026)
7. Enovis (DJO Global) DJO Global to acquire Dr Comfort (2011)
8. Aetrex Aetrex technology history (2026)